Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $38,400.00 in Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 20,000 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $1.92, for a total value of $38,400.00. Following the transaction, the insider directly owned 3,390,664 shares in the company, valued at approximately $6,510,074.88. This represents a 0.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Stock Performance

Dyadic International stock opened at $1.00 on Thursday. The stock has a fifty day moving average price of $0.78 and a 200 day moving average price of $0.83. Dyadic International Inc. has a 52 week low of $0.65 and a 52 week high of $1.35. The firm has a market capitalization of $36.33 million, a P/E ratio of -4.33 and a beta of 1.15. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Equities research analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dyadic International currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Institutional Investors Weigh In On Dyadic International

Several institutional investors and hedge funds have recently added to or reduced their stakes in DYAI. Apis Capital Advisors LLC acquired a new position in shares of Dyadic International in the 3rd quarter valued at about $1,817,000. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International during the 3rd quarter worth approximately $190,000. Marathon Capital Management increased its position in Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. Finally, Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the period. 27.95% of the stock is currently owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.